MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV
Leanne McCabe,James E. Burns,Arash Latifoltojar,Frank A. Post,Julie Fox,Erica Pool,Anele Waters,Beatriz Santana,Lucy Garvey,Margaret Johnson,Ian McGuinness,Manil Chouhan,Jonathan Edwards,Anna L. Goodman,Graham Cooke,Claire Murphy,Yolanda Collaco-Moraes,Helen Webb,Adam Gregory,Fatima Mohamed,Mary Rauchenberger,Stephen D. Ryder,Chris Sandford,Jason V. Baker,Brian Angus,Christoph Boesecke,Chloe Orkin,Shonit Punwani,Andrew Clark,Richard Gilson,David Dunn,Sarah L. Pett,the MAVMET Study group‡
DOI: https://doi.org/10.1097/qad.0000000000003947
IF: 4.632
2024-07-13
AIDS
Abstract:Increasingly, people with HIV (PWH, HIV) have a life expectancy comparable to the general population if taking effective antiretroviral therapy (ART). Consequently, the sequelae of aging including multimorbidity, have become pertinent issues. Metabolic dysfunction associated fatty liver disease (MAFLD, previously known as nonalcoholic fatty liver disease [NALFD]) is one condition that has become increasingly prevalent. MAFLD is a spectrum of disease progressing from hepatic steatosis to metabolic steatohepatitis (MASH), and ultimately, fibrosis that predisposes to end-stage liver disease and hepatocellular carcinoma. It is currently the most common global cause of chronic liver disease [1] . Previous pooled prevalence estimates observed nearly 35% of PWH have NAFLD (now MAFLD) on imaging [2] , although recent European HIV cohorts report prevalences more than 60% [3] .
immunology,infectious diseases,virology